Core Insights - The report emphasizes the continuous improvement of the global competitiveness of Chinese innovative pharmaceutical companies, focusing on innovation from both "therapeutic areas" and "technology platforms" [5][6] - The growth of commercial health insurance premiums is expected to provide new payment sources for medical expenses, as the scale of commercial health insurance is projected to reach 977.4 billion yuan by 2024 [29][30] - The report identifies potential therapeutic areas such as metabolic diseases (e.g., weight loss), chronic diseases (e.g., hypertension, hyperlipidemia), and central nervous system diseases (e.g., Alzheimer's, Parkinson's) as key focus areas for innovation [5][38] - Emerging technology platforms like small nucleic acid drugs, radioactive drugs (RDC), and CAR-T therapies are highlighted as significant areas for investment [5][38] Market Review - As of November 15, 2025, the pharmaceutical sector has outperformed the market, with the pharmaceutical index rising by 22.09% compared to a 17.62% increase in the CSI 300 index, resulting in a 4.47 percentage point outperformance [11] - The chemical preparation sector showed the best performance, increasing by 40.52%, followed by medical services (+36.98%) and chemical raw materials (+25.34%) [20] - The overall PE valuation of the pharmaceutical sector is at 30.89 times, which is relatively low compared to historical averages, indicating potential for future growth [22][23] Innovative Drugs - The report notes that the growth of health expenditures in China, which reached 9.06 trillion yuan in 2023, is outpacing GDP growth, indicating a robust market for innovative drugs [26][27] - The analysis of multinational corporations (MNCs) reveals that innovation is a core competitive advantage, with companies like Eli Lilly and Novartis showing significant growth driven by innovative products in advanced technology fields such as GLP-1 and ADC [31][32] - The report highlights the strong sales performance of GLP-1 drugs, with Eli Lilly's Mounjaro generating $6.515 billion in revenue in Q3 2025, reflecting a 109% year-on-year increase [44] CXO and Upstream - The report indicates a slight increase in pharmaceutical financing, with a recovery in business development transactions and H-share IPOs, which is expected to stimulate innovation [5] - The demand for external CXO services is growing, particularly in emerging fields such as peptides and small nucleic acids, while internal CXO orders are also showing signs of recovery [5][39] Medical Devices - The domestic medical device market is currently under pressure due to policy impacts, but improvements are anticipated as companies continue to innovate and expand internationally [5] - The report suggests that the industry fundamentals are expected to improve, with a focus on companies like Mindray Medical and Microelectrophysiology [5][39]

浦江蜿蜒，润泽上海多个产业园区；浪涛汹涌，击打出创新的节拍；货轮远航，驶向广阔的国际市 场……"十五五"规划建议擘画出未来五年的战略蓝图，一批上海科创公司为国担当、勇为尖兵，瞄准创 新与国际化"双线突围"，谋篇布局高质量发展。 硬核创新是扎根本土的底气。上海完善的科创生态，为企业攻坚"卡脖子"技术提供了肥沃土壤。乘着上 海支持创新创业的东风，80后的大学生创业者谢应波带领泰坦科技，在科学服务行业闯出一条国产化之 路；从生物材料到生物制造，凯赛生物手握颠覆性创新技术，大胆挺进合成生物产业蓝海；面对"数据 危机"带来的挑战，英方软件接连翻越研发、市场与信任"三座山"，以硬实力打造数据"保险栓"；20年 精耕细作，从3G到6G，创远信科不断夯实通信测试技术底座，用"工业之尺"刻画着产业新高度。 开放布局是链接全球的桥梁。依托上海国际科创中心的优势，科创企业家不约而同将未来五年的发展目 光投向国际市场。凯赛生物董事长刘修才说，公司要成为世界生物制造产业的开拓者，并培养中国生物 制造的同路人。在泰坦科技的"征途墙"上，董事长谢应波为"十五五"之路贴上了一个新的关键词 ——"出海"。面对海外客户对中国基础软件的偏见，英方 ...

（原标题：谢方敏辞任董事会主席兼CEO；百洋医药与多家医疗机构展开合作） 这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！ 政策动向 徐景和在受理和举报中心调研并开展接访下访 12月9日，国家药监局官微发文显示，国家药监局党组成员、副局长徐景和在受理和举报中心调研受理 和举报工作并开展接访下访，听取两家医疗器械、化妆品企业相关诉求，进行了现场沟通和答复。徐景 和指出，要科学把握安全与发展、监管与服务的关系，坚持依法行政、科学监管，有效保障企业合法权 益，助力产业高质量发展。要深刻认识当前投诉举报工作面临的新形势、新任务，坚持法治思维，依法 依规解决投诉举报事项，推进社会共治取得新成效。 药械审批 苑东生物：布瑞哌唑片获得药品注册证书 欧莱雅将增持高德美10%股份 高德美（瑞士证券交易所：股票代码为"GALD"）宣布：欧莱雅集团拟增加对该公司的股权投资，将从 Sunshine SwissCo GmbH处额外收购 10% 的股份。Sunshine SwissCo GmbH是由殷拓集团（EQT）、阿 布扎比投资局（ADIA）及Auba Investment Pte. Lt ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688513 证券简称：苑东生物 公告编号：2025-081 成都苑东生物制药股份有限公司 关于自愿披露布瑞哌唑片获得药品注册证书的公告 一、药品基本情况 药品名称：布瑞哌唑片 剂型：片剂 规格：1mg、2mg、4mg 注册分类：化学药品4类 药品有效期：12个月 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局（以下简称"国家 药监局"）核准签发的《药品注册证书》，现将相关情况公告如下： 上市许可持有人：成都苑东生物制药股份有限公司 生产企业：成都苑东生物制药股份有限公司 布瑞哌唑片活性成份为布瑞哌唑，适应症为用于治疗成人精神分裂症。 布瑞哌唑片最早由日本大冢制药（Otsuka Pharmaceutical Co.，Ltd.）开发，于2015年7月在美国获批上 市，商品名为Rexulti?，于2024年6月进口中国。国家药监局官网显示，该产品国内目前仅有进口原研药 上市，公司该药品是国内 ...

证券日报网讯 12月9日晚间，苑东生物发布公告称，公司于近日收到国家药品监督管理局核准签发的 《药品注册证书》，药品名称：布瑞哌唑片。 （文章来源：证券日报） ...

关于自愿披露布瑞哌唑片获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下简称"公司"）于近日收到国家药品监 督管理局（以下简称"国家药监局"）核准签发的《药品注册证书》，现将相关情 况公告如下： 证券代码：688513 证券简称：苑东生物 公告编号：2025-081 成都苑东生物制药股份有限公司 一、药品基本情况 药品名称：布瑞哌唑片 剂型：片剂 规格：1mg、2mg、4mg 注册分类：化学药品 4 类 药品有效期：12 个月 上市许可持有人：成都苑东生物制药股份有限公司 生产企业：成都苑东生物制药股份有限公司 药品注册标准编号：YBH29902025 受理号：CYHS2402228、CYHS2402229、CYHS2402230 证书编号：2025S03610、2025S03611、2025S03612 药品批准文号：国药准字 H20256114、国药准字 H20256115、国药准字 H20256116 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查 ...

人民财讯12月9日电，苑东生物(688513)12月9日公告，公司近日收到国家药监局核准签发的药品注册证 书，获证药品为布瑞哌唑片，该药品活性成份为布瑞哌唑，适应症为用于治疗成人精神分裂症。 ...

智通财经APP讯， 苑东生物(688513.SH)发布公告，公司于近日收到国家药品监督管理局(以下简称"国 家药监局")核准签发的《药品注册证书》。布瑞哌唑片活性成份为布瑞哌唑，适应症为用于治疗成人精 神分裂症。 布瑞哌唑片最早由日本大冢制药(Otsuka Pharmaceutical Co.，Ltd.)开发，于2015年7月在美国获批上市， 商品名为Rexulti®，于2024年6月进口中国。国家药监局官网显示，该产品国内目前仅有进口原研药上 市，公司该药品是国内首家按新注册分类获批的仿制药，视同通过一致性评价 ...

苑东生物公告，近日收到国家药品监督管理局核准签发的《药品注册证书》。药品名称为布瑞哌唑片， 剂型为片剂，规格为1mg、2mg、4mg，注册分类为化学药品4类，药品有效期为12个月。布瑞哌唑片活 性成份为布瑞哌唑，适应症为用于治疗成人精神分裂症。该药品获批，标志着该产品符合药品注册的有 关要求，不会对公司近期业绩产生重大影响。 ...

- The report introduces two key tracking indicators: "Large Order Transaction Amount Proportion" and "Net Active Buy Amount Proportion" [7] - The "Large Order Transaction Amount Proportion" is designed to capture the buying behavior of large funds. It is calculated by identifying large orders from transaction data and computing the proportion of large buy orders' transaction amounts relative to the total daily transaction amount [7] - The "Net Active Buy Amount Proportion" reflects investors' active buying behavior. It is derived by distinguishing active buy and sell transactions from transaction data, calculating the net active buy amount (active buy amount minus active sell amount), and expressing it as a proportion of the total daily transaction amount [7] Factor Backtesting Results - For individual stocks, the top 10 stocks with the highest 5-day average "Large Order Transaction Amount Proportion" include Xinhua Du (90.6%, 99.2% percentile), Beichen Industrial (89.1%, 98.8% percentile), and Zhongyou Engineering (88.8%, 100.0% percentile) [9] - For individual stocks, the top 10 stocks with the highest 5-day average "Net Active Buy Amount Proportion" include Senying Windows (22.3%, 100.0% percentile), Huitong Group (20.0%, 100.0% percentile), and Yuandong Biotech (19.6%, 100.0% percentile) [10] - For broad-based indices, the 5-day average "Large Order Transaction Amount Proportion" ranges from 71.7% (Shanghai 50 Index) to 74.3% (China Securities 500 Index), while the "Net Active Buy Amount Proportion" ranges from -5.2% (Shanghai 50 Index) to 1.9% (China Securities 500 Index) [12] - For industries, the 5-day average "Large Order Transaction Amount Proportion" is highest in the banking sector (80.6%, 86.5% percentile) and lowest in the electronics sector (70.8%, 16.4% percentile). The "Net Active Buy Amount Proportion" is highest in the steel sector (7.9%, 75.8% percentile) and lowest in the banking sector (-14.6%, 3.3% percentile) [13] - For ETFs, the top 10 ETFs with the highest 5-day average "Large Order Transaction Amount Proportion" include Guotai CSI A500 ETF (92.3%, 36.1% percentile) and Guotai SSE 10-Year Treasury Bond ETF (90.7%, 89.3% percentile) [15] - For ETFs, the top 10 ETFs with the highest 5-day average "Net Active Buy Amount Proportion" include Southern SSE STAR Chip ETF (27.5%, 100.0% percentile) and E Fund Hang Seng Dividend Low Volatility ETF (23.6%, 99.6% percentile) [16]